When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CYDY - CytoDyn on go with mid-stage study of PRO 140 in colorectal cancer
CytoDyn Inc
The FDA has signed off on a Phase 2 clinical trial evaluating CytoDyn's (OTCQB:CYDY+0.2%) leronlimab (PRO 140), combined with Bayer's Stivarga (regorafenib), in patients with metastatic colorectal cancer (mCRC).
More news on: CytoDyn Inc., Healthcare stocks news,